Purchase this article with an account.
Inna G. Georgieva, Michael H. Foerster, Antonia M. Joussen; Serum Survivin Levels In Patients With Uveal Melanoma- A Promising Biomarker?. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3288.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Detection of survivin in the serum of patients with uveal melanoma (UM) and establishment of a method by which these levels can be used as treatment predictive value
The serum samples were obtained from patients with UM (n=24) and healthy volunteers (n=23) after given informed consent. Most of the patients suffered from newly diagnosed uveal melanoma. The mean tumor prominence was 7,93mm (range 3.4-11.7mm). Five patients had metastatic disease and received chemotherapy. The mean age of patients with uveal melanoma was 67.46 years (range 36- 81).Survivin serum levels were determined using enzyme-linked immunoabsorbent assay (ELISA).
Increase of the survivin protein serum levels in patients with UM compared to the healthy controls, however without statistical significance (t-test p= 0.06). The serum levels tend to be higher in patients with a greater tumor burden or metastasis.
The first study quantifying survivin protein levels in patients with uveal melanoma.
This PDF is available to Subscribers Only